Viking Therapeutics surges as weight loss drug nears Phase 2 readout with Wall Street betting big
VKTX is not some obscure ticker anymore. Viking Therapeutics is sitting on what could be the most undervalued metabolic pipeline in biotech right now. The company’s market cap is $3.45 billion. That’s tiny compared to the size of the obesity … Read more